COVID-19: Utilizing iPS cells: Fujita Medical University and Rebirthel
-Fujita Health University, clinical trial in 2-3 years-
Fujita Health University:
On October 14, we will utilize immune cells made from human iPS cells.
The company announced that it will begin developing treatments for new coronavirus infections.
Immune cells:
Immune cells are “killer T cells” that attack virus-infected cells.
Jointly developed with “Rivercell” (Kyoto City), a venture company founded by Professor Kawamoto (Immunology) of Kyoto University.
“Rebirthel”:
Killer T cells are produced using “iPS cells stockpiled by the Kyoto University Foundation”.
The iPS cells were administered by intravenous drip and
Attacks cells infected with COVID-19,
Recover the patient.
Method using killer T cells:
“Research on antibody vaccines that bind to viruses and neutralize them” is in progress.
“A method using killer T cells that attack infected cells” is a new way of thinking.
Chunichi Shimbun Web
https://www.chunichi.co.jp/article/137318
Fujita Medical University: Concluded a joint research agreement with Rebirthel
Fujita Health University and Rebirthel:
We have signed an agreement to promote the development of new treatments for new coronavirus infections as joint research.
Department of Blood Transfusion Cell Therapy, Faculty of Medicine: Professor Miura
In charge of development in collaboration with Professor Hiroshi Kawamoto, Institute for Frontier Medical Sciences, Kyoto University, River Cell Co., Ltd.
We will work on the development of a treatment method for new coronavirus infections using “general-purpose killer T cells regenerated from iPS cells”.
Fujita Health University
https://www.fujita-hu.ac.jp/news/j93sdv0000007nf3.html
Established Rebirthel Co., Ltd.
The name is a combination of Rebirth and Cell.